The Danish maker of Ozempic and Wegovy reported a 25 percent increase in sales to $40.6 billion, but said it expected slower ...

Shares of Novo Nordisk ( NVO 4.37%) were moving higher on Wednesday. The company's stock gained 4.9% as of 1:50 p.m. ET, but ...

Novo Nordisk has a dominant position in diabetes and weight-loss drugs, strong financial growth outlook, and great potential. Click to read why NVO is a Strong Buy.

Novo Nordisk tenta ampliar o prazo da propriedade intelectual para 2036, garantindo a produção exclusiva do Ozempic no País ...

Movimento ocorre em um momento em que outras farmacêuticas brasileiras se preparam para lançar versões similares do ...

Novo Nordisk busca estender a patente do Ozempic no Brasil até 2036, mas laboratórios brasileiros já desenvolvem genéricos ...

A Sociedade Brasileira de Endocrinologia e Metabologia (SBEM), a Sociedade Brasileira de Diabetes (SBD) e a Associação Brasileira para o Estudo da Obesidade e Síndrome Metabólica (Abeso) divulgaram no ...

LONDON, Jan 30 (Reuters) - Novo Nordisk (NOVOb.CO), opens new tab will begin a late-stage trial of its experimental next-generation obesity drug CagriSema on Feb. 10 to test its long-term efficacy ...

However, Novo Nordisk (NYSE: NVO), a pioneer in the field, remains one of the leaders. That likely won't change anytime soon, since the Denmark-based pharmaceutical giant has an excellent pipeline.

The new treatment targets gut hormone GLP-1 but also mimics amylin, a hormone released by the pancreas that suppresses hunger ...